A trial comparing GEM-P chemotherapy to CHOP for people with lymphoma (CHEMO-T)

Please note - this trial is no longer recruiting patients. We hope to add results when they are available.

Cancer type:

Blood cancers
Non-Hodgkin lymphoma




Phase 2

This trial is comparing GEM-P chemotherapy to CHOP for people with T-cell lymphoma that has not been treated yet.

This trial is supported by Cancer Research UK.

More about this trial

T cell lymphoma Open a glossary item is a type of non Hodgkin lymphoma. Doctors usually treat it with CHOP chemotherapy, which is a combination of cyclophosphamide, doxorubicin and vincristine chemotherapy with prednisolone.

Sadly the cancer can come back after treatment. Doctors then use a different combination of drugs called GEM-P. This is gemcitabine and cisplatin chemotherapy with methylprednisolone.

In this trial doctors want to compare GEM-P to CHOP as a first treatment for T cell lymphoma. The aims of the trial are to find out

  • If GEM-P works better than CHOP for people with T cell lymphoma
  • About  the side effects

Who can enter

You may be able to enter this trial if you

  • Have T cell lymphoma Open a glossary item that has not been treated yet
  • Are well enough to  be up and about for at least some of each day, even if you need help looking after yourself (performance status 0, 1, 2 or 3)
  • Have lymphoma that can be measured on CT scan and is at least 1 cm across
  • Have a tissue sample of your cancer available that was taken when you were diagnosed 
  • Have satisfactory blood test results
  • Are willing to use reliable contraception during treatment and for 12 months afterwards if there is any chance that you or your partner could become pregnant
  • Are at least 18 years old

You cannot enter this trial if you

  • Have lymphoma in your brain or spinal cord (central nervous system)
  • Have lymphoma that requires radiotherapy
  • Have any other illness that is a cause for concern
  • Have problems with your heart that are a cause for concern
  • Have had any other cancer in the last 5 years, apart from carcinoma in situ of the cervix, non melanoma skin cancer or melanoma only in the outer layer of the skin (melanoma in situ) that was successfully treated
  • Have had treatment as part of another trial in the last 30 days
  • Are known to be allergic to the trial drugs
  • Are known to be HIV positive
  • Have active hepatitis B or hepatitis C
  • Are pregnant or breastfeeding

Trial design

This trial will recruit 186 people from the UK. This is a randomised trial. The people taking part are put into 2 treatment groups by a computer. Neither you nor your doctor will be able to decide which group you are in.

People in group A have CHOP. You have cyclophosphamide, doxorubicin, and vincristine through a drip into a vein once every 3 weeks and prednisolone tablets for 5 days every 3 weeks. Each 3 week period is called a cycle of treatment. You have up to 6 cycles.

People in group B have GEM-P in 4 week cycles of treatment. You have treatment for 3 weeks and then a week with no treatment.  You have gemcitabine weekly for 3 weeks and cisplatin once.  You have both these drugs through a drip into a vein. You also take methylprednisolone tablets for the first 5 days of each treatment cycle. You have up to 4 treatment cycles.

If you agree to take part in this trial, the researchers will ask for a sample of tissue taken when you had surgery to remove your cancer. They will also ask for extra blood samples for research. If you do not want to give tissue or blood samples for this study, you don’t have to. You can still take part in the trial.

Hospital visits

You will see the doctors and have some tests before you start treatment. The tests include

  • Blood tests
  • Physical examination
  • Heart trace (ECG Open a glossary item)
  • Heart scans (echocardiogram  Open a glossary itemor MUGA) (not everyone)
  • Urine test
  • Blood tests
  • CT scan
  • Bone marrow test
  • PET scan

You have blood tests and see the doctors often while you are having treatment.

You have 3 CT scans while you are having treatment and a PET scan 28 days after you finish chemotherapy.  You have another CT scan 3 and 12 months after finishing treatment.

Some people need a bone marrow test when they finish treatment. Your doctor will discuss this with you.

The research team see you 30 days after you finish treatment then 3, 6, 9 and 12 months later. They then see you once a year for 5 years.

Side effects

The most common side effects of CHOP are

The most common side effects of GEM-P are

  • A drop in blood cells causing an increased risk of infection, bleeding problems, tiredness and breathlessness
  • Sore mouth
  • Numbness and tingling in your hands and feet (peripheral neuropathy)
  • Indigestion
  • Hair loss
  • A change in appetite
  • Changes to how food tastes
  • Changes in blood sugar levels
  • Ringing in your ears (tinnitus)

We have more information about

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Professor David Cunningham

Supported by

Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
The Royal Marsden NHS Foundation Trust

Other information

This is Cancer Research UK trial number CRUKE/11/020

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:


Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Cara took part in a clinical trial

A picture of Cara

"I am glad that taking part in a trial might help others on their own cancer journey.”

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think